Moderna Inc. ($MRNA) Stock Forecast: Up 6.7% Today

What is Moderna Inc.?

Moderna Inc. (MRNA) is a leading biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines. Today, the stock had a strong bullish movement amidst recent market developments.

Why is Moderna Inc. going up?

MRNA stock is up 6.7% on Feb 13, 2026 20:36

• Moderna's stock experienced a bullish movement as the company exceeded fourth-quarter revenue expectations, driven by better-than-expected sales of its Covid vaccine.
• The positive outlook for Moderna can also be attributed to the overall market sentiment, with U.S. consumer prices rising less than anticipated, providing a boost to investor confidence.
• The increased capital injection into Jiuzi Holdings by multiple crypto investment institutions may have also contributed to a positive market sentiment, indirectly benefiting Moderna and other companies in the market.
• Analysts closely monitoring Moderna's performance amidst competition in the biotech space, particularly in the kidney disease portfolio and the expanding applications of its drugs, could have further fueled investor optimism in the stock.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

BridgeBio Pharma, DoorDash, Nvidia, Rio Tinto: What brokers said this week

This article summarizes recent broker commentary and news affecting several major companies including BridgeBio Pharma, DoorDash, Nvidia, and Rio Tinto. Key updates include BridgeBio Pharma's positive Phase 3 results, analyst expectations for DoorDash's earnings, UBS raising Nvidia's price target, and accelerated activity at Rio Tinto's Simandou iron ore project. It also covers other market movements, earnings reports, and analyst ratings for various companies across different sectors.

https://www.proactiveinvestors.com/companies/news/1087375/bridgebio-pharma-doordash-nvidia-rio-tinto-what-brokers-said-this-week-1087375.html

Amid a positive outlook, multiple crypto investment institutions complete US$60 million capital injection into Jiuzi Holdings, increasing the original planned amount by 50% Jzxn's DAT strategy enters scaled implementation phase

Multiple crypto investment institutions have completed a $60 million capital injection into Jiuzi Holdings, exceeding the original planned amount by 50%. This significant investment signals a positive outlook for Jiuzi Holdings and supports the scaled implementation of JZxn's DAT strategy. The news was published on February 13, 2026, at 8:00 AM EST.

https://www.marketscreener.com/news/amid-a-positive-outlook-multiple-crypto-investment-institutions-complete-us-60-million-capital-inj-ce7e5ddadd80f027

Applied Materials, Arista, Moderna, Coinbase, DraftKings, Steel Dynamics, Rivian, Roku, and More Movers

This article highlights several companies as "movers" in the stock market, including Applied Materials, Arista, Moderna, Coinbase, DraftKings, Steel Dynamics, Rivian, and Roku. The market experienced a modest uplift on Friday, following news that U.S. consumer prices in January rose by 2.4%, which was lower than anticipated by economists.

https://www.barrons.com/articles/stock-movers-9b7eaa16?gaa_at=eafs&gaa_n=AWEtsqdA6byPmpV5f1__7UxtYM4D_UZ3CTX0LuiqyeeT-RWMHjdtx9mpN1O_&gaa_ts=698f37c5&gaa_sig=iyGsizCUauvZ_5ZuuL95HY9Xmvvd5iZu4IbBMe2N91CC54kdKhC5EU-0-f5afZyN76dGdTGERWatGQAZndmpzQ%3D%3D

All Eyes On Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts

Analysts are closely observing Vertex Pharmaceuticals' kidney disease portfolio, particularly the IgAN drug povetacicept, as its late-stage RAINIER study is progressing smoothly with data expected in the first half of 2026. While the company's nonopioid painkiller Journavx is seeing incremental growth, competition is heating up in the IgAN space. Vertex also plans to expand povetacicept's use into neurology for generalized myasthenia gravis, despite growing competition in that area.

https://www.biospace.com/business/all-eyes-on-vertexs-kidney-franchise-as-painkiller-journavx-tops-half-a-million-scripts

Moderna Sales Beat as Covid Shot Demand Falls Less Than Expected

Moderna Inc. exceeded fourth-quarter revenue expectations, driven by its Covid vaccine sales declining less than anticipated. The company reported $678 million in sales, surpassing the average Wall Street estimate of $625 million. This resulted in a narrower adjusted loss per share compared to the previous year.

https://www.bloomberg.com/news/articles/2026-02-13/moderna-sales-beat-as-covid-shot-demand-falls-less-than-expected

Trending Today

Moderna Inc. Price History

11.01.2026 - MRNA Stock was down 9.3%

• A recent FDA decision on Moderna's flu vaccine application is seen as a setback for the company's vaccine pipeline, potentially influencing the bearish movement in the stock.
• However, the acceptance of mRNA-1010 for review in various regions such as the EU, Canada, and Australia may offer some comfort to investors, mitigating the overall impact on Moderna's financial prospects.
• The company's new five-year vaccine agreement with the Mexican government has the potential to counterbalance the negative sentiment from the FDA decision, indicating a strategic move for revenue growth and expansion into new markets.
• The market's response to Moderna's bearish trend today may reflect the varied reports on its vaccine developments and collaborations, with investors keen on monitoring the firm's regulatory advancements and commercial ventures in the future.

11.01.2026 - MRNA Stock was down 15.2%

• The FDA rejection of Moderna's flu vaccine application likely contributed to the bearish movement in MRNA stock. This setback could have raised concerns among investors about the company's pipeline and future revenue streams.
• Despite the FDA rejection, Moderna's strategic agreements with the Mexican government and local pharmaceutical companies could provide a potential revenue boost in the long term. However, the immediate market reaction seems to have been overshadowed by the negative news of the flu vaccine application rejection.
• The news of Moderna's acceptance for review in other regions like the EU, Canada, and Australia might have mitigated some of the stock's losses, indicating potential global market opportunities for the company.
• Overall, the market movement in MRNA today reflects a mix of regulatory challenges and strategic partnerships, showcasing the volatility and resilience of the biopharmaceutical sector.

06.01.2026 - MRNA Stock was down 6.1%

• The stock experienced a bearish movement, possibly due to the anticipation of its upcoming quarterly earnings projecting a loss per share and lower revenue than expected.
• Recent insider selling activity might have also contributed to the negative sentiment surrounding the stock.
• The launch of leveraged ETFs tied to the company's share prices could have amplified the downward pressure on the stock as traders adjusted their positions based on market volatility and risk factors associated with leveraged products.

05.01.2026 - MRNA Stock was down 6.2%

• Moderna's stock experienced a bearish movement possibly due to legal uncertainties surrounding its mRNA vaccine technology in the Arbutus v. Moderna patent infringement case.
• The market may have reacted negatively to the summary judgment rulings issued by Judge Wolson, which could impact Moderna's vaccine sales and ongoing legal battles.
• Despite advancements in oncology and promising clinical trial results in the industry, the specific legal challenges faced by Moderna might have overshadowed positive developments in the broader healthcare sector.
• Investors might be cautious about the implications of the legal proceedings on Moderna's revenue and market position, leading to the bearish movement in the stock price.

10.01.2026 - MRNA Stock was up 8.9%

• Today, Moderna's positive stock movement is linked to the favorable investor sentiment surrounding its advancements in cancer vaccine development and its overall market success.
• A strategic partnership with Mexico to bolster vaccine manufacturing capacity and provide respiratory vaccines has likely instilled confidence in investors regarding Moderna's growth prospects.
• Endorsement by Jim Cramer as a top-performing stock of the year has also bolstered Moderna's positive momentum, showcasing its resilience and future potential.
• Projected revenue growth in 2026 and ongoing research and development endeavors by key players in the biotechnology sector, including Moderna, point towards a promising outlook for the company's future performance.

10.01.2026 - MRNA Stock was up 5.4%

• Moderna's positive performance today is linked to the strategic agreement reached with Mexico, which not only strengthens its global presence but also augments its revenue potential.
• Despite initial concerns stemming from a Sell rating and low price target by Bank of America Securities, news of the partnership with Mexico overshadowed these sentiments, boosting investor confidence.
• Collaborations such as the one with Recordati to advance investigational therapeutics highlight Moderna's diversification efforts beyond COVID-19 vaccines, further bolstering its long-term growth outlook.
• The overall optimistic trend in the biotechnology sector, especially within the United States market poised for significant advancements, likely contributed to the favorable stance on Moderna's stock today.

10.01.2026 - MRNA Stock was up 5.4%

• Moderna saw a surge in its stock value today due to recent strategic partnerships and agreements with the Mexican government. These initiatives aim to expand geographically, bolster local vaccine production, and fortify its position in global markets.
• The favorable reception from investors towards Moderna, acknowledged by notable market analysts, has also contributed to its upward movement as one of the standout stocks presently. Investor enthusiasm is fueled by Moderna's growth trajectory and promising ventures in cancer vaccines.
• Market response indicates a strong belief in Moderna's future revenue growth forecasts and its dedication to improving pandemic readiness and public health responses, exemplified by collaborations such as the one with Mexico.
• In essence, Moderna's positive market performance today reflects a blend of well-thought-out business strategies and optimistic market sentiment towards the company's expansion plans and groundbreaking vaccine technologies.

02.01.2026 - MRNA Stock was up 5.3%

• Moderna's upward momentum can be associated with the encouraging insights shared during the 44th Annual J.P. Morgan Healthcare Conference. The company emphasized its strategic business expansion, progress in product development, and anticipated financial performance over the upcoming years.
• The market responded positively to Moderna's detailed three-year business plan revealed during its Analyst Day. The plan included forecasts for revenue growth, expansion of its vaccine portfolio, and a heightened focus on oncology and rare disease treatments.
• Investors seemingly responded to Moderna's growth potential, despite concerns raised regarding declining revenue and projected performance compared to industry standards. The optimistic narrative presented by Moderna during recent conferences likely overshadowed these underlying challenges in the near term.

12.01.2026 - MRNA Stock was up 8.6%

• Moderna's stock experienced a strong bullish movement following the news of a five-year agreement with Mexico to enhance mRNA vaccine supply for respiratory diseases. This collaboration not only expands Moderna's market reach but also signifies its commitment to global health initiatives.
• The FDA's rejection of Moderna's flu vaccine application might have initially caused some uncertainty in the market. However, the positive development with Mexico and the focus on respiratory vaccines could have overshadowed this setback, driving the bullish momentum.
• The market seems to be reacting favorably to Moderna's strategic partnerships and long-term growth prospects, positioning the company as a key player in the biotech industry. Investors are likely viewing Moderna as a solid investment choice amidst ongoing advancements in medical technology and global health priorities.

03.01.2026 - MRNA Stock was down 7.0%

• Despite a positive performance over the past year and year-to-date, Moderna's stock witnessed a bearish movement today. This comes in light of successful partnerships and promising experimental vaccines.
• The robust financial results and pipeline progress of Merck & Co. may have diverted investor attention from Moderna, impacting MRNA's stock adversely.
• Moderna's announcement of an upcoming webinar on decision intelligence for an autonomous cold chain underscores its dedication to innovation. However, this development might not have been sufficient to counter the prevailing market sentiment affecting MRNA's stock.
• The FDA's recent request for monitoring myocarditis in a new COVID antibody trial possibly added to market uncertainty. This factor could have influenced the bearish movement in Moderna's stock observed today.

13.01.2026 - MRNA Stock was up 7.3%

• Moderna experienced a strong bullish movement today as its sales beat expectations, driven by robust demand for its Covid-19 vaccine, which declined less than anticipated.
• The positive sales performance indicates that Moderna continues to play a significant role in the global vaccination efforts, contributing to its revenue growth.
• The market's reaction to Moderna's sales beat showcases investor confidence in the company's ability to navigate through changing demand dynamics for Covid-19 vaccines.
• The news of Moderna's sales exceeding estimates likely fueled investor optimism and contributed to the bullish movement in the stock price.

13.01.2026 - MRNA Stock was up 6.7%

• Moderna's stock experienced a bullish movement as the company exceeded fourth-quarter revenue expectations, driven by better-than-expected sales of its Covid vaccine.
• The positive outlook for Moderna can also be attributed to the overall market sentiment, with U.S. consumer prices rising less than anticipated, providing a boost to investor confidence.
• The increased capital injection into Jiuzi Holdings by multiple crypto investment institutions may have also contributed to a positive market sentiment, indirectly benefiting Moderna and other companies in the market.
• Analysts closely monitoring Moderna's performance amidst competition in the biotech space, particularly in the kidney disease portfolio and the expanding applications of its drugs, could have further fueled investor optimism in the stock.